Patients
About T-Cell Acute Lymphoblastic Leukemia/ Lymphoma
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) are rare and aggressive blood cancers that affect T lymphocytes in both adults and children.
These two conditions are closely related. In T-ALL, the disease mainly involves the bone marrow and blood. In T-LL, the cancer cells are primarily found in lymph nodes or other tissues, with less involvement of the bone marrow. Despite these differences, they are biologically similar and are often treated using comparable approaches.
While many patients respond to initial treatment, some may experience relapse or may not respond adequately to therapy (refractory patients). In these situations, additional treatment options may be needed.
What is CAR-T cell therapy?
CAR-T cell therapy is a type of immunotherapy that uses a patient’s own T cells, a type of immune cell that helps the body fight disease. In this approach, T cells are collected from the patient and modified in a specialized laboratory to better recognize and target cancer cells. Once prepared, the modified cells are infused back into the patient, where they are designed to identify and attack the cancer cells.
CAR-T therapies are currently being investigated and, in some cases, approved for certain types of blood cancers.
CARxALL Trial
OC-1 is an investigational CAR-T therapy currently being studied in a clinical trial for patients with relapsed or refractory T-ALL. Some T-ALL and T-LL cancer cells express a protein called CD1a on their surface. This clinical trial is studying OC-1, an investigational CAR-T therapy designed to recognize cells that express CD1a.
The purpose of this study is to evaluate the safety and potential activity of OC-1. Participation in a clinical trial is voluntary and requires meeting specific eligibility criteria.
Who may be eligible?
Eligibility is determined by the study doctor and includes medical criteria such as:
- Being older than 2 years (children or adults).
- Having T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/T-LL) with CD1a positivity.
- Having disease that has returned after treatment or has not responded to previous therapies, including relapse after a stem cell transplant.
What does participation involve?
Participation in a clinical trial may include:
- Medical screening tests
- Hospital-based treatment and monitoring
- Follow-up visits
The study team will provide detailed information and answer any questions before participation.
How to Learn More
If you are interested in learning more about this clinical trial, you may consult the public clinical trial registry: CAR x ALL trial
Important Information
OC-1 is an investigational therapy and has not been approved by regulatory authorities. Its safety and efficacy are currently under evaluation.